The Galien Forum USA 2019

PANEL
1

Chair
MaryAnne Rizk, PhD
Senior Vice President, Digital R&D Strategy
IQVIA

Panelists
Nancy Dreyer PhD, MPH, FISPE, Fellow DIA
Chief Scientific Officer
IQVIA

Emmanuel Fombu, MD, MBA
Physician, Author: The Future of Healthcare

Karl Hick
Chief Digital & Information Officer
Takeda

Jim Scholefield, MBA
Executive Vice President,
Chief Information
and Digital Officer

Merck & Co.

Panel Intro

Sponsored by

IQVIA logo

Digital Health Transformation – Orchestrating patient-centricity from molecule to market


Chair
MaryAnne Rizk, PhD
Senior Vice President Digital R&D Strategy
IQVIA

Dr. MaryAnne Rizk has been a rising global digital technology life science executive for the past 20+ years, transforming the way the biopharmaceutical industry manages digital health to improve patient outcomes. Effective in building enterprise alliance programs, Dr. Rizk has forged clinical outsourcing collaborations to improve patient centricity across hundreds of global life science stakeholders across Pharma, Biotech, Medical Device through tech-enabled services via CROs. With a proven track record in the SaaS sales and marketing, Dr. Rizk has shaped high-performance teams, working cross-functionally to increasing customer value. She brings broad-based expertise in leading SaaS channel programs to support growth strategies and deliver profitable revenue under complex, dynamic market conditions.

At IQVIA, Dr. Rizk is responsible for driving the digital R&D transformation breakthroughs from molecule to market via the Orchestrated Clinical Trials (OCT) SaaS platform. The first of its kind end-to-end clinical technology platform leverages embedded intelligence, unparallel data, and analytics to trigger a series of orchestrated automation around patient-centric workflows and supporting trial automation to lead precision therapies to market smarter and faster competitively. Before IQVIA, MaryAnne has globally lead both Oracle and Medidata’s strategic channel partnership strategy to enables organizations to leverage innovative SaaS cloud-based platform technologies to accelerate drug/device development. Leveraging her systems engineering background, MaryAnne had started her career at Merck by leading the charge to retire legacy paper-based processes to gain operational excellence and earlier digital insights while adhering to patient-centric clinical care.  She’s spent time at the clinical site-level to engage in how data is being collected by clinicians and brought her insights back to coach and translate meaningful functionality required to the R&D engineering teams.

In additional to driving platform adoptions across several leading industry clinical solutions, she has been an advocate and trusted advisor to shape the emerging technology revolution of Big Data fueling AI, Machine Learning, and Blockchain adoption. MaryAnne is an accomplished speaker and has participated on over 30+ publications with industry peers and has spoken at 50+ industry sessions to continue to advocate the meaningful value of technology, translated into improved clinical patient care as well as satisfying significant business outcomes.

Dr. Rizk has received her Bachelor of Engineering and Masters in Technology Management from Stevens Institute of Technology. She also completed her Ph.D. in Technology Management, specializing her dissertation and research in Pharmaceutical Strategic Partnerships. Dr. Rizk holds various board, chair and leadership memberships and is a proud member of the following networks: Healthcare Businesswomen’s Association (HBA), New York Health Business Leaders (NYHBL), Drug Information Association (DIA), Society of Clinical Data Management (SCDM) and Society of Clinical Research (SCRS).


Nancy_Dreyer

Nancy Dreyer PhD, MPH, FISPE, Fellow DIA
Chief Scientific Officer
IQVIA

Nancy Dreyer is Chief Scientific Officer and Senior Vice President at IQVIA.  She focuses on generating real-world evidence for regulators, clinicians, patients and payers through pragmatic trials and non-interventional approaches and has more than 200 publications on real-world evidence, including the popular book, Registries for Evaluating Patient Outcomes: A User’s Guide, now in its 4th edition. She is also known for creating the GRACE Checklist, the only validated checklist for measuring the quality of observational studies of comparative effectiveness. ​Her diverse experience includes serving as a member of the PCORI Clinical Trials Methods Advisory Panel and a Standing Consultant to the National Football League Health & Safety Executive Committee.  She is a Fellow of both the Drug Information Association (DIA) and the International Society of Pharmacoepidemiology, and is an Adjunct Professor of Epidemiology at the Gillings School of Global Public Health at the University of North Carolina.  Her experience includes serving as CEO and Founder of Epidemiology Resources Inc., where she launched the journal, Epidemiology and led the New England Epidemiology Institute summer training program, and as a Senior Vice President at UnitedHealth’s Ingenix/i3 division.  In 2019 she received the DIA Global Inspire Award for Author of the Year for “Advancing a framework for regulatory use of real world evidence: When real is reliable,“ the most downloaded article in 2018 in Therapeutic Innovation & Regulatory Science.


Emmanuel Fombu, MD, MBA
Physician, Author: The Future of Healthcare

Dr Fombu is an internationally recognized authority on the convergence of digital technologies and healthcare. He is an award winning author, physician, pharmaceutical executive and healthcare futurist with over 15 years combined experience in clinical medicine, drug development, digital medicine, pragmatic trials and product lifecycle management strategy in the healthcare industry and private equity.

His current focus is on how digital technologies can be leveraged to better measure healthcare related product’s real world effectiveness and value in partnership with digital health startups, payers and providers.

In addition to his book, The Future of Healthcare: Human and Machine Partnering for Better Outcomes, Dr. Fombu has authored multiple research papers and abstracts in renowned peer reviewed journals. He is a champion and advocate for value based healthcare, personalized medicine, nanotechnology, blockchain, big data, artificial intelligence, machine learning and digital medicine. He serves as an external advisory board member at the Massachusetts Institute of Technology’s MIT.nano project.

Dr Fombu completed his clinical training at Emory-Crawford Long Hospital and holds an MBA from both Cornell University’s Johnson School of Business and Queen’s University’s Smith School of Business. He lives in New York City.


Karl Hick

Karl Hick
Chief Digital & Information Officer
Takeda

Karl Hick is the Chief Digital & Information Officer at Takeda Pharmaceuticals. His nearly 20 years of experience in technology ranges from the transformation of IT organizations to mergers, acquisitions, and divestitures, to cutting-edge digital health. Impacting patients’ lives has become a meaningful value-driver in Karl’s 12+ years in the pharmaceutical industry.

Takeda is a global, values-based R&D-driven biopharmaceutical company, where Karl has led the efforts to create a diversified technology investment portfolio including digital and AI. He has accelerated the strategic digital agenda through a Digital Advisory Board (DAB), demonstrating the value of cross-functional collaboration for a faster and more significant impact. Karl also serves as the Chairman of the Board of Managers for HATCH@Takeda. HATCH is a venture fund focused on inventing and investing in digital health companies to improve patient outcomes.

With the $62B acquisition of Shire in January, Karl has been focused on guiding the organization through the integration while driving digital innovation. He was the Chief Information Officer (CIO) at Shire before moving to Takeda in November 2017. Before joining Shire in 2013, Karl was the CIO of Novartis Vaccines and Diagnostics. Throughout his career, Karl has been actively engaged in contributing to the technology community through his participation in various CIO Executive forums and his championing of technology development programs to increase diversity and inclusion.

Born in Greece, Karl went to university in the US and China. He received his bachelor’s degree in Mechanical Engineering from Georgia Institute of Technology in Atlanta, Georgia, and completed a Technology Executive Leadership program at IMD in Lausanne, Switzerland.


Jim ScholefieldJim Scholefield, MBA
Executive Vice President, Chief Information
and Digital Officer

Merck & Co.

Jim Scholefield is Executive Vice President, Chief Information and Digital Officer at Merck & Co., Inc., and a member of Merck’s Executive Committee. His broad portfolio of responsibilities includes enterprise-wide information technology solutions and digital transformation strategies focused on developing and implementing new and emerging technologies to further enable invention and support the company’s mission.

Previously, he was global chief information officer of NIKE, Inc., where he led delivery of innovation solutions that improved global business integration, resulting in a more flexible IT infrastructure.

Prior to that role Jim served as chief technology officer of The Coca-Cola Company, responsible for its IT strategy, technology engineering and technology operations worldwide. Earlier he held IT leadership roles at Northern Trust, the Ford Motor Company, and Procter and Gamble.

He has served on the board of directors at Stanley Black & Decker since November 2017.

Jim received a Bachelor of Science in Management from Florida State University and a combined Master of Science in Management and MBA degree from the Georgia Institute of Technology.